KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Research & Development (2016 - 2025)

Historic Research & Development for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $523.7 million.

  • BeOne Medicines' Research & Development rose 553.89% to $523.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 877.5%. This contributed to the annual value of $2.0 billion for FY2024, which is 982.24% up from last year.
  • Per BeOne Medicines' latest filing, its Research & Development stood at $523.7 million for Q3 2025, which was up 553.89% from $524.9 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Research & Development peaked at $542.0 million during Q4 2024, and registered a low of -$556.3 million during Q4 2021.
  • Over the past 5 years, BeOne Medicines' median Research & Development value was $446.0 million (recorded in 2022), while the average stood at $388.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 25646.44% in 2021, then soared by 18017.83% in 2022.
  • Over the past 5 years, BeOne Medicines' Research & Development (Quarter) stood at -$556.3 million in 2021, then surged by 180.18% to $446.0 million in 2022, then rose by 10.75% to $494.0 million in 2023, then grew by 9.72% to $542.0 million in 2024, then dropped by 3.39% to $523.7 million in 2025.
  • Its Research & Development was $523.7 million in Q3 2025, compared to $524.9 million in Q2 2025 and $481.9 million in Q1 2025.